Actovegin, 40 mg/ml 2 ml 5 pcs

Antihypoxant. Actovegin® is a hemoderivative, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass through).

Positive effects on glucose transport and utilization, stimulates oxygen consumption (which leads to stabilization of plasma cell membranes during ischemia and reduction of lactate formation) thus possessing antihypoxic effect which starts to show at the latest 30 min after parenteral administration and reaches a maximum on average in 3 h (2-6 h).

Actovegin® increases concentrations of ATP, ADP, phosphocreatine and the amino acids glutamate, aspartate and GABA.

The effects of the drug Aktovegin® on oxygen uptake and utilization as well as its insulin-like activity with stimulation of glucose transport and oxidation are significant in the treatment of diabetic polyneuropathy.

In patients with diabetes mellitus and diabetic polyneuropathy Actovegin® reliably decreases symptoms of polyneuropathy (stabbing pain, burning sensation, paresthesia, numbness of lower extremities). Sensory disorders are objectively reduced and patients’ mental well-being improves.

Indications

– metabolic and vascular disorders of the brain (including. ischemic stroke, craniocerebral trauma;

– peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers);

– diabetic polyneuropathy;

– wound healing (ulcers of various etiologies, burns, trophic disorders (bedsores), disorders of wound healing processes);

– prevention and treatment of radiation injuries of the skin and mucous membranes in radiation therapy.

Active ingredient

Deproteinized calf blood hemoderivative

Composition

1 ml Aktovegin concentrate (in terms of dry deproteinized calf blood hemoderivate) 40 mg

Auxiliary substances:

water d / i – up to 2 ml.

.

How to take, the dosage

B/a, IV (including as an infusion) and IM. Due to the potential for anaphylactic reactions, it is recommended to test before starting the infusion.

Metabolic and cerebral vascular disorders: from 5 ml to 25 ml (200-1000 mg) daily by IV for 2 weeks with subsequent change to Aktovegin® in tablet form.

Ischemic stroke: 20-50 ml (800-2000 mg) in 200-300 ml of 0.9% sodium chloride solution or 5% dextrose solution, by IV drip daily for 1 week, then 10-20 ml (400-800 mg) by IV drip – 2 weeks with subsequent change to Actovegin® tablet form.

Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml (800-1000 mg) of drug in 200 ml of 0.9% sodium chloride solution or 5% dextrose solution, w/a or IV daily; duration of treatment about 4 weeks.

Diabetic polyneuropathy: 50 ml (2000 mg) per day by IV for 3 weeks with subsequent change to Actovegin® in tablet form – 2-3 tablets. 3 times per day for at least 4-5 months.

Wound healing: 10 ml (400 mg) intravenously or 5 ml intravenously daily or 3-4 times a week depending on healing process (in addition to local administration of Actovegin® in dosage forms for local use).

Prevention and treatment of radiation lesions of the skin and mucous membranes in radiation therapy: The average dose is 5 ml (200 mg) by IV daily during intervals of radiation exposure.

Radiation cystitis: 10 ml (400 mg) transurethral daily in combination with antibiotic therapy. The infusion rate is about 2 ml/min. The duration of treatment is determined individually according to the symptoms and severity of the disease.

Interaction

It is currently unknown.

Special Instructions

In case of the intravenous route of administration, administer slowly not more than 5 ml.

Because of the possibility of anaphylactic reactions, a test injection (2 ml in mM) is recommended.

The solution for injection has a slightly yellowish tint. The intensity of the coloration may vary from batch to batch depending on the characteristics of the starting materials used, but this does not adversely affect the activity or tolerability of the drug.

Do not use an opaque solution or a solution containing particles.

Contraindications

– hypersensitivity to Actovegin® or similar drugs;

– decompensated heart failure;

– pulmonary edema;

– oliguria, anuria;

– fluid retention in the body.

With caution: hyperchloremia, hypernatriemia.

.

Side effects

Allergic reactions: skin rash, skin hyperemia, hyperthermia, up to and including anaphylactic shock.

.

Pregnancy use

The use of the drug in pregnant women has not caused adverse effects on the mother or fetus. However, the potential risk to the fetus must be considered when using in pregnant women.

.